title: Effect of oral L-carnitine on serum myoglobin in hemodialysis patients.
abstract: Oral L-carnitine has been reported to lower the elevated serum myoglobin of renal failure in chronic peritoneal dialysis patients, and intravenous L-carnitine can improve muscle fatigue and cramps in chronic hemodialysis patients. In this study oral L-carnitine, 1.98 g/day, was administered to 6 chronic hemodialysis patients for 8 weeks. Serum levels of myoglobin, creatine kinase, and aldolase, as well as skeletal muscle symptoms (cramps during dialysis, fatigue, and weakness) were monitored biweekly for 12 weeks. Mean baseline serum myoglobin level was 337 +/- 34 ng/mL. By 6 and 8 weeks mean serum myoglobin was 234 +/- 39 and 233 +/- 40 ng/mL, significantly lower by the Friedman test (p < 0.05). Four weeks after carnitine was discontinued, mean serum myoglobin had risen to 320 +/- 118 ng/mL. Serum creatine kinase and aldolase levels were normal throughout the study. All 6 patients noted improvement in muscular symptoms, with maximal effect at 8 weeks, although 2 patients did not improve until 2 to 4 weeks after carnitine was stopped. We conclude that oral L-carnitine may lower serum myoglobin and improve muscle cramps and weakness in hemodialysis patients. The maximal effect of carnitine on myoglobin occurs 2 weeks before the maximal improvement in muscular symptoms.
authors.affiliation: Department of Medicine, Nassau County Medical Center, East Meadow, New York 11554, USA.
authors.forename: D A
authors.initials: DA
authors.lastname: Feinfeld
authors.forename: P
authors.initials: P
authors.lastname: Kurian
authors.forename: J T
authors.initials: JT
authors.lastname: Cheng
authors.forename: G
authors.initials: G
authors.lastname: Dilimetin
authors.forename: M R
authors.initials: MR
authors.lastname: Arriola
authors.forename: L
authors.initials: L
authors.lastname: Ward
authors.forename: T
authors.initials: T
authors.lastname: Manis
authors.forename: C P
authors.initials: CP
authors.lastname: Carvounis
mesh_terms: D000284:Administration, Oral; D002331:Carnitine / Q000008:administration & dosage*; D004341:Drug Evaluation; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy; D009135:Muscular Diseases / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D009211:Myoglobin / Q000097:blood / Q000187:drug effects*; D006435:Renal Dialysis / Q000009:adverse effects; D013997:Time Factors
chemical_list: D009211:Myoglobin; D002331:Carnitine